Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

Ultragenyx hopes to expand its bone disease franchise in a deal that frees up Mereo to focus on its anti-TIGIT immuno-oncology pipeline asset.

The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.